Pure Global AI
NCT06061263Recruitment Completed

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy

The Patterns and Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve Pathologic Complete Response to Neoadjuvant Chemoradiotherapy
Sun Yat-sen UniversityClinicalTrials.govother
Verified
Study focus
Disease/Condition
Esophageal Cancer
Drug/Device/Intervention
follow up
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
May 01, 2022
End date
Dec 01, 2023
Enrollment
96 participants
Primary outcome

recurrence-free survival

Summary

It has been reported that patients with esophageal squamous cell carcinoma who achieved
 pathological complete response (PCR) to neoadjuvant chemoradiotherapy have better survival
 than those with non-PCR. Howeve, there is still recurrent diseases developed in PCR patients
 after esophagectomy. Herein, we aimed to investgate the risk factors of recurrence in PCR
 patients.

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06061263
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06061263 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-sen University and is currently Recruitment Completed. The study focuses on Esophageal Cancer. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.